From December 10 to 13, 2022 the annual meeting of the American Society of Hematology (ASH) took place in the vibrant city of New Orleans, Louisiana, and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results.

In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from these studies may have.

First, Hofland talks with Thomas G. Martin, MD.

Thomas G. Martin, MD.

Martin is the Associate Director of the University of California San Francisco Myeloma Program and Director of the Unrelated Donor Transplantation program for adults at UCSF Medical Center.

Advertisement #3

Martin’s research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants, and he is involved in efforts to improve outcomes for patients who have transplants from unrelated donors.

In this episode Hofland and Martin talk about updated results from a Phase 1b expansion study evaluating subcutaneous administration of Isatuximab-irfc (Sarclisa®; Sanofi) by an on-body delivery system in combination with pomalidomide (Pomalyst®; Bristol-Myers Squibb Company) and dexamethasone in patients with relapsed/refractory multiple myeloma. How does subcutaneous delivery vs. intravenous administration of Isatuximab benefits patients? Hofland and Martin also talk about the results of a Subgroup Analysis of the IKEMA trial.

Monica Soni, MD

Then, in the second half of the program, Hofland talks with Monica Soni, MD, Director of Specialty Care for the Los Angeles County Department of Health Services, the second-largest municipal health system in the United States. She is also an assistant clinical professor within the UCLA Department of Medicine.

Soni is commitment to improving quality, equity and affordability in health care.

In this episode Hofland and Soni talks about the results of a study in which the investigators looked at the utilization of bone-modifying agents (BMA) in the treatment of multiple myeloma, particularly among Medicaid patients.

What invesrigatriors found was shocking!

About The Onco’Zine Brief
The Onco’Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco’Zine Brief or how to sponsor or support this public radio broadcast and podcast, Download our Media Kit, or visit our Patreon page.

  • To sign up for The Onco’Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee and RoastMasterZ.

Clinical trial
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA) – NCT03275285

Highlights of Prescribing Information
Isatuximab-irfc (Sarclisa®; Sanofi) [Prescribing information]
Pomalidomide (Pomalyst®; Bristol-Myers Squibb Company) [Prescribing Information]

Advertisement #5